Advanced Accelerator Applications goes public

Advanced Accelerator Applications, a French company that specializes in molecular nuclear medicine, has debuted its IPO after pricing its over 4.6 million shares at $16 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “AAAP. Citigroup Global Markets Inc and Jefferies LLC are the lead underwriters. The company’s backers include HBM Healthcare Investments.


10 November 2015, Saint-Genis-Pouilly, France – Advanced Accelerator Applications S.A. (“AAA” or the “Company”), an international specialist in Molecular Nuclear Medicine (MNM), today announced the pricing of its initial public offering of 4,688,000 American Depositary Shares (“ADSs”) representing 9,376,000 of its ordinary shares at a price of $16.00 per ADS.

The ADSs are expected to begin trading on the Nasdaq Global Select Market on November 11, 2015 under the ticker “AAAP.” All of the ADSs are being offered by AAA. In addition, AAA has granted the underwriters a 30-day option to purchase up to 703,200 additional ADSs from the Company at the initial public offering price, less underwriting discounts.

Citigroup Global Markets Inc. and Jefferies LLC are acting as joint book-running managers for the offering. Canaccord Genuity Inc. and JMP Securities LLC are acting as co-managers.

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer of ADSs in any Member State of the European Economic Area which has implemented the Prospectus Directive (each, a “Relevant Member State”) will be made pursuant to an exemption under the Prospectus Directive, as implemented in that Relevant Member State, from the requirement to publish a prospectus for offers of securities.

The offering will be made only by means of a prospectus, copies of which may be obtained, when available, from Citigroup Global Markets Inc. by calling toll-free (800) 831-9146 or from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022 or by calling (877) 547-6340 or by emailing

About Advanced Accelerator Applications
Advanced Accelerator Applications (AAA) is a radiopharmaceutical company founded in 2002 to develop innovative molecular nuclear medicine products. AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (“Personalized Medicine”).